Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis

Archives of Neurology

Volumn 68, Issue 4, 2011, Pages 480-487

  Buck, Dorothea ^a   Cepok, Sabine ^a   Hoffmann, Steve ^b   Grummel, Verena ^a   Jochim, Angela ^a   Berthele, Achim ^a   Hartung, Hans Peter ^c   Wassmuth, Ralf ^d   Hemmer, Bernhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON ANTIBODY; BETA1A INTERFERON; DRUG ANTIBODY; HLA DR ANTIGEN; INTERFERON BETA SERINE; UNCLASSIFIED DRUG;

ALLELE; ANTIBODY PRODUCTION; ARTICLE; CAPTURE ENZYME LINKED IMMUNOSORBENT ASSAY; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE IDENTIFICATION; GENETIC MARKER; GENOTYPE; GERMANY; HUMAN; IMMUNOASSAY; IN VIVO MYXOVIRUS PROTEIN A ASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; ALLELES; AUTOANTIBODIES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENOTYPE; HLA-DR ANTIGENS; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 79953847674     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.65     Document Type: Article

References (40)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221- 1231. (Pubitemid 34304266)
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
3. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747. (Pubitemid 40563183)
4. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet. 2008;9(7):516-526. (Pubitemid 351861542)
5. Hafler DA, Compston A, Sawcer S, et al; International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357(9):851-862. (Pubitemid 47347319)
6. Paty DW, Li DK; UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):662-667.
7. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
8. Jacobs LD, Cookfair DL, Rudick RA, et al; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294.
9. Stüve O, Bennett JL, Hemmer B, et al. Pharmacological treatment of early multiple sclerosis. Drugs. 2008;68(1):73-83. (Pubitemid 350275685)
10. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24(11):1720-1740, discussion 1719.
11. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K; Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology. 2005;65(1):33-39. (Pubitemid 40967773)
12. Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P. Immunogenicity of interferon beta: differences among products. J Neurol. 2004;251(suppl 2):II15-II24.
13. Farrell RA, Giovannoni G. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler. 2007;13(5):567-577. (Pubitemid 46939521)
14. Gneiss C, Reindl M, Berger T, et al. Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res. 2004;24(5):283-290. (Pubitemid 38648309)
15. Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology. 2009;73(18):1493-1500.
16. van der Voort LF, Visser A, Knol DL, Oudejans CB, Polman CH, Killestein J. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. Eur J Neurol. 2009;16(9):1049-1052.
17. Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFNbeta antibodies on MRI lesions of MS patients in the BECOME study. Neurology. 2009;73(18):1485-1492.
18. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology. 1996;47(4):889-894.
19. Sorensen PS, Ross C, Clemmesen KM, et al; Danish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362(9391):1184-1191.
20. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact. an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007;68(13):977-984. (Pubitemid 46569129)
21. Ravnborg M, Bendtzen K, Christensen O, et al. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Mult Scler. 2009;15(3):323-328.
22. Hemmer B, Stüve O, Kieseier B, Schellekens H, Hartung HP. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol. 2005;4(7):403-412. (Pubitemid 40826532)
23. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol. 2005;5(11):853-865. (Pubitemid 41581667)
24. Sundberg EJ, Deng L, Mariuzza RA. TCR recognition of peptide/MHC class II complexes and superantigens. Semin Immunol. 2007;19(4):262-271. (Pubitemid 47043487)
25. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1* 0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis [published correction appears in Am J Hum Genet. 2008;83(4):541]. Am J Hum Genet. 2008;83(2):219-227.
26. Bein G, Gläser R, Kirchner H. Rapid HLA-DRB1 genotyping by nested PCR amplification. Tissue Antigens. 1992;39(2):68-73.
27. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology. 2003;61(10):1444-1446. (Pubitemid 37463391)
28. Pachner A, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn. 2003;7(1):17-25. (Pubitemid 37339029)
29. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006;15(18):2813-2824. (Pubitemid 44400408)
30. Sellebjerg F, Krakauer M, Hesse D, et al. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol. 2009;16(12):1291-1298.
31. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology. 2009;73(5):372-377.
32. Kappos L, Clanet M, Sandberg-Wollheim M, et al; European Interferon Beta-1a IM Dose-Comparison Study Investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology. 2005;65(1):40-47.
33. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology. 2000;48(2):95-100. (Pubitemid 30608666)
34. Sørensen PS, Deisenhammer F, Duda P, et al; EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol. 2005;12(11):817-827. (Pubitemid 41597593)
35. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9(7):740-750.
36. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS; Danish Multiple Sclerosis Group. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2006;12(3):247-252.
37. van der Voort LF, Gilli F, Bertolotto A, et al. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol. 2010;67(4):402-407.
38. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs. 2009;23(5):379-396.
39. Panitch H, Goodin DS, Francis G, et al; EVIDENCE Study Group (EVidence of Interferon Dose-response: European North American Comparative Efficacy); University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002;59(10):1496-1506.
40. Durelli L, Verdun E, Barbero P, et al; Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453-1460.